NuCana Plc (NCNA)
4.05
-0.22
(-5.15%)
USD |
NASDAQ |
Dec 11, 16:00
4.00
-0.05
(-1.23%)
Pre-Market: 09:22
NuCana Research and Development Expense (Quarterly): 2.928M for Sept. 30, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Adaptimmune Therapeutics Plc | 25.95M |
| Biodexa Pharmaceuticals Plc | -- |
| Autolus Therapeutics Plc | 27.72M |
| Mereo BioPharma Group Plc | 4.244M |
| Bicycle Therapeutics Plc | 65.65M |